Table 3 Summary of the differences in the application of immune checkpoint inhibitors against common tumors, according to FDA approval information
From: Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
Condition | Drug | ORR (%) | mPFS (months) | mOS (months) | Grade 3–5 AE (%) | Approval time | Key trials |
|---|---|---|---|---|---|---|---|
Melanoma | Ipilimumab | 16.8 | 2.70 | 11.2 | 11 | 03/2011 | NCT00324155 |
Ipilimumab + nivolumab | 60 | 8.50 | Not reached | 62 | 10/2015 | CheckMate-067 | |
Pembrolizumab | 37 | 5.00 | >  24 | <  10 | 09/2014 | KeyNote-001 | |
Nivolumab | 32 | 4.70 | 17.3 | 9 | 12/2014 | CheckMate-037 | |
Atezolizumab | 60 | 15.10 | 16.1 | 33.5 | 07/2020 | IMspire150 | |
NSCLC | Nivolumab | 20 | 3.50 | 9.2 | 7 | 03/2015 | CheckMate-063; CheckMate-017 |
Ipilimumab + nivolumab | 36 | 5.1 | 17.1 | 58 | 05/2020 | CheckMate-227 | |
Pembrolizumab | 19.4 | 4.00 | 12.7 | <  10 | 10/2015 | KeyNote-001; KeyNote-010 | |
Atezolizumab | 17 | 2.70 | 12.6 | 11 | 10/2016 | Poplar (NCT01903993) | |
Durvalumab | 28.4 | 16.80 | 23.2 | 29.9 | 02/2018 | NCT02125461 | |
Cemiplimab | 39 | 8.20 | Not reached | 28 | 02/2021 | NCT03088540 | |
RCC | Nivolumab | 25 | 4.60 | 25 | 19 | 11/2015 | CheckMate-025 |
Ipilimumab + nivolumab | 41.6 | 11.6 | Not reached | 65 | 04/2018 | CheckMate-214 | |
Pembrolizumab | 59.3 | 15.10 | Not reached | 75.8 | 04/2019 | KeyNote-426 | |
Avelumab | 51.4 | 13.80 | 11.6 | 71.2 | 05/2019 | JAVELIN Renal 101 | |
HCC | Nivolumab | 14.3 | 4.00 | 15 | 25 | 09/2017 | CheckMate-040 |
Ipilimumab + nivolumab | 33 | 8.3 | 17.5 | 37 | 03/2020 | Checkmate-040 | |
Pembrolizumab | 17 | 4.9 | 12.9 | 26 | 11/2018 | KeyNote-224 | |
Atezolizumab | 65 | 6.80 | Not evaluated | 56.5 | 05/2020 | IMbrave150 | |
SCLC | Nivolumab | 12 | 1.4 | 5.6 | 45 | 08/2018 | CheckMate-032 |
Atezolizumab | 60.2 | 5.20 | 12.3 | 37 | 03/2019 | Impower133 | |
Pembrolizumab | 19 | 2.0 | 8.7 | 31 | 06/2019 | KeyNote-158; KeyNote-028 | |
Durvalumab | 68 | 5.10 | 13 | 62 | 03/2020 | CASPIAN (NCT03043872) | |
CRC | Nivolumab | 32 | 14.30 | 5.6 | 45 | 08/2017 | CheckMate-142 |
Ipilimumab + nivolumab | 55 | 12 | Not evaluated | 20 | 07/2018 | CheckMate-8HW | |
Pembrolizumab | 43.8 | 16.50 | 13.7 | 22 | 06/2020 | KeyNote-177 |